CRBN is also required for the anti-MM action of the thalidomide derivatives lenalidomide and pomalidomide; decreasing the expression of CRBN results in resistance to IMiDs, as evidenced by both in vitro and clinical studies [144–148]. Here, CRBN is linked to Miyoshi myopathy.